Galileo – Biotech Innovation Fund BC USD

Reference Data

ISIN LU2226244361
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund BC USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 37.57 USD 02.06.2025
Previous Price * 38.39 USD 30.05.2025
52 Week High * 65.08 USD 17.07.2024
52 Week Low * 33.21 USD 09.04.2025
NAV * 37.57 USD 02.06.2025
Issue Price * 37.57 USD 02.06.2025
Redemption Price * 37.57 USD 02.06.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 24,951,021
Unit/Share Assets *** 24,039,913
Trading Information SIX

Performance

YTD Performance -20.01% 30.12.2024
02.06.2025
YTD Performance (in CHF) -27.24% 30.12.2024
02.06.2025
1 month -6.64% 02.05.2025
02.06.2025
3 months -13.09% 03.03.2025
02.06.2025
6 months -31.85% 02.12.2024
02.06.2025
1 year -36.94% 03.06.2024
02.06.2025
2 years -40.91% 02.06.2023
02.06.2025
3 years -41.53% 02.06.2022
02.06.2025
5 years -74.95% 31.03.2021
02.06.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 9.28%
Arcellx Inc 8.53%
Poseida Therapeutics Inc Ordinary Shares 7.94%
Alnylam Pharmaceuticals Inc 4.07%
Stoke Therapeutics Inc 3.30%
Sarepta Therapeutics Inc 3.13%
Iovance Biotherapeutics Inc 2.90%
Q32 Bio Inc 2.41%
Rocket Pharmaceuticals Inc 2.27%
CRISPR Therapeutics AG 2.20%
Last data update 30.11.2024

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee ***
Ongoing Charges *** 0.44%
SRRI ***
SRRI date *** 31.05.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)